

## Biosketch: Uwe Siebert

Uwe Siebert, MD, MPH, MSc, ScD  
*Professor of Public Health & Medical Decision Making (UMIT)*  
*Adjunct Prof. of Health Policy & Management (Harvard University)*  
*Past-President, Society for Medical Decision Making (SMDM)*  
Chair, Department of Public Health, Health Services Research  
and Health Technology Assessment, UMIT  
Director, Division for HTA, ONCOTYROL – Center for Personalized  
Cancer Medicine  
Director, Cardiovascular Research Program, Institute for  
Technology Assessment, Dept. of Radiology, Massachusetts  
General Hospital, Harvard Medical School

UMIT - University for Health Sciences,  
Medical Informatics and Technology  
Eduard-Wallnoefer-Zentrum 1  
A-6060 Hall i.T., Austria  
Phone: +43-50-8648-3930  
Fax: +43-50-8648-673931  
Email direct: [uwe.siebert@umit.at](mailto:uwe.siebert@umit.at)  
Email PA: [public-health@umit.at](mailto:public-health@umit.at)  
Web: [www.umit.at/dph](http://www.umit.at/dph)



Prof. Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health, Medical Decision Making and Health Technology Assessment (HTA), is the Chair of the Department of Public Health, Health Services Research and HTA at UMIT - University for Health Sciences, Medical Informatics and Technology in Austria and the Director of the Division for HTA in the ONCOTYROL – Center for Personalized Cancer Medicine in Austria. He is also Adjunct Professor of Health Policy and Management at the Harvard T.H. Chan School of Public Health and Director of the Program on Cardiovascular Research at the Institute for Technology Assessment and Department of Radiology at the Massachusetts General Hospital, Harvard Medical School, Boston. He is the course director of the Harvard summer course on ‘Decision Analysis in Clinical Research’ and he has an adjunct teaching appointment at the School of Public Health and Epidemiology at the University of Munich.

After medical school, he worked for several years as a physician in international public health projects in West-Africa, Brazil, and Germany. He then earned an MPH at the Munich School of Public Health, and completed an MSc in Epidemiology and a ScD in Health Policy and Management with a concentration in decision sciences at the Harvard School of Public Health. Before he started his faculty position at Harvard Medical School, he was the Director of the Bavarian Public Health Research and Coordinating Center at the University of Munich, Germany, and completed Visiting Scholarship at the Harvard Center for Risk Analysis.

His research interests include applying evidence-based quantitative and translational methods from public health, epidemiology, comparative effectiveness research, health services and outcomes research, economic evaluation and decision sciences in the framework of HTA as well as in the clinical context of routine health care and patient guidance. His current substantive research focuses on cancer, cardiovascular disease, diabetes, hepatitis C, neurological disorders, and others. His methodological research includes evaluations of public health interventions, prevention/screening, diagnostic imaging procedures, personalized medicine, causal inference from “big” data, decision modelling, and study designs controlling for treatment switching. He has been leading projects/work packages in several EU FP7 and H2020 projects (e.g., ELSA-GEN, BiomarCaRE, MedTechHTA, EUthyroid, FORECEE, MDS-RIGHT, EUREGIO-EFH). He teaches courses in decision-analytic modeling, HTA, economic evaluation, analysis of big data, and causal inference at several universities and for industry in Europe, USA, South America, and Asia.

Prof. Siebert is the Past-President of the *Society for Medical Decision Making (SMDM)*, a member of the *Latin America Consortium Advisory Committee of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)*, member of the ‘*National HTA Strategy*’ Expert Group of the Austrian Federal Ministry of Health, member of the *Oncology Advisory Council of the Federal Ministry of Health* in Austria, member of the *Advisory Board of the GÖG - National Austrian Public Health Institute*, member of the *Austrian Cochrane Collaboration Branch*, and a member of several national and international Directors Boards (*Society for Medical Decision Making; Austrian Society of Epidemiology, German Network of EbM; German Association for Medical Informatics, Biometry and Epidemiology*). He has served as Vice President of *SMDM*, and a member of the *ISPOR Board of Directors*, the *Directors Board of the German Competence Network Heart Failure*, the *International Expert Committee Advising the Institute for Quality and Efficiency in Health Care (IQWiG) on the Methods for Economic Evaluations of Health Care Interventions*, the *Harvard Flagship Initiative in Comparative Effectiveness Research*, the Extended Board of Directors of the *German Association of Health Economics*, and the *Advisory Board of the Ludwig Boltzmann Institute for HTA* in Austria.

He is the *Clinical Guideline Commissioner for the Association of the Scientific Medical Societies in Germany (AWMF)* and the Chairman of the *Working Groups ‘Health Economics’ and ‘Medical Decision Making’* of the *German Society for Medical Informatics, Biometry and Epidemiology (GMDS)*. He is Co-Chair of the *ISPOR-SMDM Modeling Good Research Practices Task Force*, Co-Chair of the ‘*Issues in Methodology Section*’ of the *SMDM Policy Initiative*, and a Leadership Member of the *ISPOR Personalized/Precision Medicine Special Interest Group*.

He has worked with several HTA Agencies (e.g., DAHTA@DIMDI/Germany, IQWiG/Germany, NICE/UK, ANVISA/Brazil, CADTH/Canada, LBI-HTA/Austria, GÖG/Austria) and he advises government agencies, academic institutions and industry regarding the conduction and impact of health technology assessments on policy and reimbursement decisions. He has authored more than 350 publications including HTA reports, textbook chapters, scientific articles, and editorials, and is Editor of the *European Journal of Epidemiology*, as well as editorial board member of several scientific journals.

## Selected Publications (from more than 350 publications; for full publication list 2006-now, see: [www.umit.at/dph](http://www.umit.at/dph))

- Hillemanns P, Friese K, Dannecker C, Klug S, Seifert U, Iftner T, Hädicke J, Löning T, Horn L, Schmidt D, Ikenberg H, Steiner M, Freitag U, **Siebert U**, Sroczynski G, Sauerbrei W, Beckmann MW, Gebhardt M, Friedrich M, Münstedt K, Schneider A, Kaufmann A, Petry KU, Schäfer APA, Pawlita M, Weis J, Mehnert A, Fehr M, Grimm C, Reich O, Arbyn M, Kleijnen J, Wesselmann S, Nothacker M, Follmann M, Langer T, Jentschke M. Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/0270L, December 2017) – Part 1 and 2. *Geburtshilfe Frauenheilkd.* 2019;79(2):148-176.
- Kristensen FB, Husereau D, Augustovski F, Berger ML, Bond K, Booth A, Bridges JFP, Drummond M, Grimshaw J, Hui M, Ijzerman MJ, Jonsson E, Ollendorf DA, Rütger A, **Siebert U**, Sharma J, Wailoo A. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. *Value in Health* 2019 [in press].
- Siebert U; Hallsson LR. To stop or not to stop: a value of information view. [Commentary]. *European Journal of Epidemiology* 2018;33(9):785-787.
- Veličković VM, Borisenko O, Svensson M, Spelman T, **Siebert U**. Congenital heart defect repair with ADAPT tissue engineered pericardium scaffold: An early-stage health economic model. *PLoS ONE* 2018;13(9): e0204643. <https://doi.org/10.1371/journal.pone.0204643>.
- Veličković VM, Rochau U, Conrads-Frank A, Kee F, Blankenberg S, **Siebert U**. Systematic assessment of decision-analytic models evaluating diagnostic tests for acute myocardial infarction based on cardiac troponin assays. *Expert Review of Pharmacoeconomics & Outcomes Research* 2018;18(6):619-640. doi: 10.1080/14737167.2018.1512857
- Rajsic S, Gothe H, Borba HH, Sroczynski G, Vujicic J, Toell T, **Siebert U**. Economic burden of stroke: a systematic review on post-stroke care. *Eur J Health Econ.* 2018 [in press]. <https://doi.org/10.1007/s10198-018-0984-0>.
- Schnell-Inderst P, Hunger T, Conrads-Frank A, Arvandi M, **Siebert U**. Ten recommendations for assessing the comparative effectiveness of therapeutic medical devices: A targeted review and adaptation. *J Clin Epidemiol.* 2018;94:97-113.
- Christensen KD, Uhlmann WR, Roberts JS, Linnenbringer E, Whitehouse PJ, Royal CDM, Obisesan TO, Cupples LA, Butson MB, Fasaye GA, Hiraki S, Chen CA, **Siebert U**, Cook-Deegan R, Green RC. A randomized controlled trial of disclosing Genetic risk information for Alzheimer's disease via telephone. *Genetics in Medicine* 2018;20(1):132-141.
- Seidl A, Danner M, Wagner C, Sandmann FG, Sroczynski G, Stürzlinger H, Zsifkovits J, Schwalm A, Lhachimi SK, **Siebert U**, Gerber-Grote A. Estimation of Input Costs for a Markov Model in a German Health Economic Evaluation of Newer Antidepressants. *MDM Policy & Practice* 2018;1-11.
- Perleth M, Schnell-Inderst P, Rütger A, Raatz H, Kolominsky-Rabas P, Panteli D, **Siebert U**, Berndt N, Wahlster P. Das Curriculum Health Technology Assessment (HTA), Version 2.0, GMS Health Technology Assessment 2017;13:Doc03:1-10.
- Mühlberger N, Boskovic K, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Sroczynski G, **Siebert U**. Benefits and Harms of Prostate Cancer Screening - Predictions of the ONCOTYROL Prostate Cancer Outcome and Policy Model. *BMC Public Health* 2017;17(1):596, doi: 10.1186/s12889-017-4439-9. [Open Access: <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4439-9>]
- Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, Paulden M, Bundo M, Stenehjem D, Brixner D, Krahn M, **Siebert U**. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. *BMC Cancer* 2017 Oct 16;17(1):685 [in press]. doi: 10.1186/s12885-017-3603-z.
- Schnell-Inderst P, Iglesias CP, Arvandi M, Ciani O, Matteucci Gothe R, Peters J, Blom AW, Taylor RS, Sculpher M, **Siebert U**. Synthesis of RCT and observational data: A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement. *Health Economics* 2017;26(Suppl. 1):46-69.
- Di Paolo A, Sarkozy F, Ryll B, **Siebert U**. Personalized medicine in Europe: not yet personal enough? *BMC Health Services Research* 2017 [in press].
- Latimer NR, Henshall C, **Siebert U**, Bell H. Treatment Switching: statistical and decision-making challenges and approaches. *International Journal of Technology Assessment in Health Care* 2016;32(3):160-6.
- Hunger T, Schnell-Inderst P, Sahakyan N, Siebert U. Using expert opinion in health technology assessment: a guideline review. *International Journal of Technology Assessment in Health Care* 2016;1-9.
- Jahn B, Rochau U, Kurzthaler C, Paulden M, Kluibenschädl M, Arvandi M, Kühne F, Goehler A, Krahn M, **Siebert U**. Lessons learned from a cross-model validation between a discrete event simulation model and a cohort state-transition model for personalized breast cancer treatment. *Medical Decision Making* 2016;36(3):375-90.
- Ultsch B, Damm O, Beutels P, Bilcke J, Bruggenjurgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, **Siebert U**, Wasem J, Wichmann O. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. *Pharmacoeconomics* 2016;34(3):227-44.
- Christensen KD, Dukhovny D, **Siebert U**, Green RC. Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. [Review]. *Journal of Personalized Medicine* 2015;5(4):470-86.
- Willenbacher E, Weger R, Rochau U, **Siebert U**, Willenbacher W, on behalf of the Austrian Myeloma Registry (AMR). Real-world use of 3rd line therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) analysis of the therapeutic landscape and clinical outcomes prior to the use of next generation myeloma therapeutics. *PLoS ONE* 2016;11(3): e0147381.
- Völzke H, Caron P, Dahl L, de Castro JJ, Erlund I, Gaberšček S, Gunnarsdottir I, Hubalewska-Dydejczyk A, Ittermann T, Ivanova L, Karanfilski B, Khattak RM, Kusić Z, Laurberg P, Lazarus JH, Markou KB, Moreno-Reyes R, Nagy EV, Peeters RP, Pirāgs V, Podoba J, Rayman MP, Rochau U, **Siebert U**, Smyth PP, Thuesen BH, Troen A, Vila L, Vitti P, Zamrazil V, Zimmermann MB, John Lazarus, for the Iodine Global Network (IGN) West Central Europe group. Ensuring effective prevention of iodine-deficiency disorders. *Thyroid* 2016;26(2):189-96.
- Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, Flatscher-Thoeni M, Schnell-Inderst P, Sroczynski G, Lackner M, Schall I, Hebborn A, Pugner K, Fehervary A, Brixner D, **Siebert U**. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. *Journal of Comparative Effectiveness Research* 2015;4(5):485-504.
- Mühlberger N, Kurzthaler C, Iskandar R, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, **Siebert U**. The ONCOTYROL Prostate Cancer Outcome and Policy Model – Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening. *Medical Decision Making* 2015 [Epub ahead of print]
- Jahn B, Rochau U, Kurzthaler C, Paulden M, Kluibenschädl M, Arvandi M, Kühne F, Goehler A, Krahn M, **Siebert U**. Lessons learned from a cross-model validation between a discrete event simulation model and a cohort state-transition model for personalized breast cancer treatment. *Medical Decision Making* 2015 [Epub ahead of print]
- Siebert U**, Arvandi M, R MG, Bornschein B, Eccleston D, D LW, Rankin J, De Bruyne B, Fearon WF, Pijs NH, Harper R. Improving the Quality of Percutaneous Revascularisation in Patients with Multivessel Disease in Australia: Cost-Effectiveness, Public Health Implications, and Budget Impact of FFR-Guided PCI. *Heart Lung Circ* 2014;527-533.
- Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G, **Siebert U**. Medical decision analysis for first-line therapy of chronic myeloid leukemia. *Leuk Lymphoma* 2014;55(8):1758-67.
- Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, den Ruijter H, Schnabel RB, Kee F, Salomaa V, **Siebert U**, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S on behalf of the BiomarcARE consortium. BiomarcARE - rationale and design of the European BiomarcARE Project including 300,000 participants from 13 European countries. *Eur J Epidemiol.* 2014;29(10):777-90.
- Siebert U**, Rochau U, Claxton K. When is Enough Evidence Enough? – Using Systematic Decision Analysis and Value-of-Information Analysis to Determine the Need for Further Evidence. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen - German Journal for Quality in Health Care* 2013;107(7):575-84.
- Siebert U**, Wurm J, Matteucci-Gothe R, Arvandi M, Vavricka S, von Kaenel R, Begre S, Sulz M, Meyenberger C, Sagmeister M, Group SICS. Predictors of Temporary and Permanent Work Disability in Patients with Inflammatory Bowel Disease Results of the Swiss Inflammatory Bowel Disease Cohort Study. *Inflammatory Bowel Diseases* 2013;19(4):847-855.

Sroczyński G, **Siebert U**. Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. *Nature Reviews Gastroenterology & Hepatology* 2013;10(10):572-4.

**Siebert U**, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -3. *Medical Decision Making* 2012;32(5):690-700.

**Siebert U**, Rochau U. Personalized Cancer Therapy. [German]. *PharmacoEconomics* 2012;10:87-104.

Caro JJ, Briggs AH, **Siebert U**, Kuntz KM, on Behalf of the ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force -1. *Value in Health* 2012;15:796-803.

**Siebert U**. [Transparent Decisions in Public Health Using Systematic Decision Analysis]. [German]. In: Schwartz FW, Badura B, Busse R, Leidl R, Raspe H, Siegrist J, Walter U (eds.): [The Public Health Book. Health and Health Care]. 3<sup>rd</sup> ed. Urban & Fischer: Munich, 2012,485-502.

Sroczyński G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Kramer A, **Siebert U**. Cost-effectiveness of primary HPV screening for cervical cancer in Germany - a decision analysis. *Eur J Cancer* 2011;47(11):1633-46.

Luce BR, Drummond MF, Dubois RW, Neumann PJ, Joensson B, **Siebert U**, Schwartz JS. Principles for planning and conducting comparative effectiveness research. *Journal of Comparative Effectiveness Research* 2012;1(5):431-40.

Fearon WF, Bornschein B, Tonino PA, Gothe RM, Bruyne BD, Pijls NH, **Siebert U**. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. *Circulation* 2010;122(24):2545-50.

Caro JJ, Nord E, **Siebert U**, McGuire A, McGregor M, Henry D, de Pouvourville G, Atella V, Kolominsky-Rabas P. The efficiency frontier approach to economic evaluation of health-care interventions. *Health Econ* 2010;19(10):1117-27.

Oberaigner W, **Siebert U**. Do women with cancer have better survival as compared to men after adjusting for staging distribution? *Eur J Public Health* 2010.

Sroczyński G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, **Siebert U**. [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]. *Health Technology Assessment*. Cologne: DIMDI, 2010;1-127.

Sroczyński G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem Z, **Siebert U**. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. *J Viral Hep* 2010;17(1):34-50.

Pijls NH, Fearon WF, Tonino PA, **Siebert U**, Ikeno F, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrom T, Oldroyd KG, Ver Lee PN, McCarthy PA, De Bruyne B, FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. *J Am Coll Cardiol* 2010;56(3):177-84.

Schnell-Inderst P, Schwarzer R, Gohler A, Grandi N, Grabein K, Stollenwerk B, Manne J, Klauss V, **Siebert U**, Wasem J. Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. *Int J Technol Assess Health Care* 2010;26(1):30-9.

Tonino PAL, De Bruyne B, Pijls NHJ, **Siebert U**, Ikeno F, van't Veer M, Klauss V, Manoharan G, Engström T, Oldroyd KG, Ver Lee PN, McCarthy PA, Fearon WF, for the FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *New England Journal of Medicine* 2009;360(3):213-24.

**Siebert U**, Bornschein B, Schnell-Inderst P, Rieber J, Pijls N, Wasem J, Klauss V. Measurement of Fractional Flow Reserve to Guide the Decision on Percutaneous Coronary Interventions. *Health Technology Assessment* Vol. 15-04. (Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health). Cologne: DIMDI, 2008.

Drummond MF, Schwartz JF, Jönsson BJ, Luce BR, Neumann PJ, **Siebert U**, Sullivan SD. Key principles for the improved conduct of health technology assessments for resource allocation decisions. *International Journal of Technology Assessment in Health Care* 2008;24(3):244-258.

Ammenwerth E, Schnell-Inderst P, Machan C, **Siebert U**. The effect of electronic prescribing on medication errors and adverse drug events: A systematic review. *Journal of the American Medical Informatics Association*. 2008;15(5):285-600.

Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, Stollenwerk B, **Siebert U**. Progression-free survival as a surrogate endpoint in advanced breast cancer. *International Journal of Technology Assessment in Health Care* 2008;24(4):371-83.

Lettmeier B, Mühlberger N, Schwarzer E, Sroczyński G, Wright D, Zeuzem S, **Siebert U**. Market Uptake of New Antiviral Drugs for the Treatment of Hepatitis C. *Journal of Hepatology* 2008;49(4):528-36.

Mühlberger N, Sroczyński G, Esteban E, Mittendorf T, Miksad RA, **Siebert U**. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. *Int J Technol Assess Health Care* 2008;24(2):184-92

Institute for Quality and Efficiency in Health Care (IQWiG). Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System. V. 1.0. (Members of the IQWiG International Expert Panel: Attella V, Caro J, Pouvourville G, Henry D, McGregor M, McGuire A, Nord E, **Siebert U**) Cologne: IQWiG; 2008, 69 pages.

**Siebert U**. Cost-Effectiveness. In: King SP III and Yeung AC (eds.). *Interventional Cardiology*. McGraw-Hill, New York: 2007; 767-82.

**Siebert U**, Sroczyński G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, Voigt K, Gibis B, Hölzel D, Goldie SJ. The German Cervical Cancer Screening Model: Development and validation of a decision-analytic model for cervical cancer screening in Germany. *Eur J Pub Health* 2006;16(2):185-92.

**Siebert U**, Januzzi JL Jr, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. *American Journal of Cardiology*, 2006;98(6):800-5.

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, **Siebert U**, Price A, Stein K. The cost-effectiveness of testing for hepatitis C in former injecting drug users. *Health Technol Assess* 2006;10(32):1-112.

Göhler A, Januzzi JL, Worrell SS, Osterziel KJ, Gazelle GS, Dietz R, **Siebert U**. A Systematic Meta-Analysis of the Efficacy and Heterogeneity of Disease Management Programs in Congestive Heart Failure. *J Cardiac Failure* 2006;12(7):554-67.

**Siebert U**. Using Decision-Analytic Modeling to Transfer International Evidence from Health Technology Assessment to the Context of the German Health Care System. A HTA Methods Report. *Health Technology Assessment* Vol 15. Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security. 90 pages. Cologne: DIMDI, 2005.

**Siebert U**, Sroczyński G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. *Int J Technol Assess Health Care* 2005;21(1):55-65.

**Siebert U**, Bornschein B, Walbert T, Dodel R. Systematic assessment of decision models in Parkinson's disease. *Value Health* 2004;7(5):610-26.

**Siebert U**, Muth C, Sroczyński G, Velasco-Garrido M, Gerhardus A, Gibis B (eds.). Liquid-Based Preparation and Computer-Assisted Examination of Cervical Smears in Cervical Cancer Screening. Clinical Effectiveness, Economic Evaluation, and Decision Analysis. *Health Technology Assessment* Vol 35. Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health. Sankt Augustin: Asgard, 2004;444 pages

Robins JM, Hernán MA, **Siebert U**. Estimations of the Effects of Multiple Interventions. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, eds. *Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors*. Vol. 1. Geneva: World Health Organization, 2004; 2191-2230.

**Siebert U**, Sroczyński G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB. Cost-effectiveness of peginterferon  $\alpha$ -2b plus ribavirin versus interferon  $\alpha$ -2b plus ribavirin for initial treatment of chronic hepatitis C. *Gut* 2003; 52(3): 425-32.

**Siebert U**. When should decision-analytic modeling be used in the economic evaluation of health care?. *The European Journal of Health Economics* 2003;4(3):143-50.